Peter Farrell Sells 8,000 Shares of ResMed (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) Director Peter Farrell sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the sale, the director directly owned 52,773 shares in the company, valued at approximately $11,873,925. This trade represents a 13.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Price Performance

NYSE:RMD opened at $211.84 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The company has a 50 day moving average price of $200.49 and a 200-day moving average price of $222.23. ResMed Inc. has a 1-year low of $180.26 and a 1-year high of $293.81. The firm has a market cap of $30.73 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 1.36 and a beta of 0.76.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 EPS for the quarter, beating the consensus estimate of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.86%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter last year, the business earned $2.55 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Equities research analysts forecast that ResMed Inc. will post 12.02 EPS for the current year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Stockholders of record on Thursday, August 20th will be given a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.2%. This is a boost from ResMed’s previous quarterly dividend of $0.60. The ex-dividend date is Thursday, August 20th. ResMed’s dividend payout ratio (DPR) is presently 23.14%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Piper Sandler dropped their price target on shares of ResMed from $233.00 to $225.00 and set a “neutral” rating on the stock in a research note on Friday. KeyCorp dropped their target price on shares of ResMed from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday. JPMorgan Chase & Co. started coverage on shares of ResMed in a research note on Wednesday, April 15th. They set an “overweight” rating for the company. Wells Fargo & Company reduced their price target on shares of ResMed from $225.00 to $215.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Evercore set a $255.00 price target on shares of ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, ResMed currently has a consensus rating of “Hold” and an average target price of $240.17.

Institutional Investors Weigh In On ResMed

Hedge funds have recently modified their holdings of the business. Jones Financial Companies Lllp grew its stake in ResMed by 52.6% during the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock valued at $645,000 after acquiring an additional 994 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of ResMed in the 2nd quarter valued at $389,000. Brown Advisory Inc. grew its holdings in shares of ResMed by 17.8% during the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 240 shares during the period. Cresset Asset Management LLC purchased a new stake in ResMed in the 2nd quarter valued at about $206,000. Finally, Alliancebernstein L.P. increased its position in shares of ResMed by 24.2% during the second quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock valued at $73,808,000 after acquiring an additional 55,790 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, beating the approximately $2.89–$2.90 consensus and rising from $2.55 a year earlier. Revenue increased 8.6% year over year to $1.46 billion, in line with estimates. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its quarterly dividend from $0.60 to $0.66 per share, a 10% increase. The dividend is payable September 24 to shareholders of record on August 20, supporting ResMed’s income-investment appeal. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Positive Sentiment: Royal Bank of Canada raised its price target to $244 from $234 while retaining a “sector perform” rating, indicating potential upside from recent trading levels. Benzinga analyst action
• Neutral Sentiment: Analyst sentiment remains mixed. Piper Sandler lowered its target to $225 and Wells Fargo cut its target to $215; both maintain neutral or equal-weight ratings. The overall analyst consensus remains “Hold,” despite a consensus target near $246. ResMed Analyst Ratings
• Negative Sentiment: The primary pressure on RMD is forward guidance: fiscal 2027 revenue expectations reportedly trail consensus, raising concerns that growth may moderate even after the quarterly earnings beat. RMD Stock Down Despite Q4 Earnings Beat
• Negative Sentiment: Director Peter Farrell sold 8,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 plan, reducing its negative signaling value, but it may add modest short-term selling pressure. SEC Insider Trading Filing

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.